A Model for Setting Performance Objectives for Salmonella in the Broiler Supply Chain

A stochastic model for setting performance objectives for Salmonella in the broiler supply chain was developed. The goal of this study was to develop a model by which performance objectives for Salmonella prevalence at various points in the production chain can be determined, based on a preset final performance objective at the end of the processing line. The transmission of Salmonella through the broiler production chain was modeled. The prevalence at flock level was calculated from the measured prevalence at sample level. The transmission model is based on data on the occurrence of Salmonella collected in the Dutch broiler production chain during several years. The developed model can be used by policymakers and industry to determine economically and politically acceptable performance objectives for various points of the production chain and to draw conclusions about which interventions are most appropriate.     

When Everyone Is an Orphan: Against Adopting a U.S.-Styled Orphan Drug Policy in Canada

Putting aside whether diseases that affect only small numbers of people (“rare diseases”) should be prioritized over diseases that are otherwise orphaned, in this article I argue that a new approach to rare, orphan diseases is needed. The current model, first signaled by the United States' Orphan Drug Act and subsequently emulated by several other jurisdictions, relies on a set of open-ended criteria and market-based incentives in order to define and encourage drug therapies for rare, orphan diseases. Given a) the biopharmaceutical industries' growing interest in orphan diseases, b) progress in the sphere of personalized medicines enabling more and more common diseases to be reclassified as rare, and c) empirical evidence suggesting that the most orphan drugs target only a limited, lucrative subset of rare diseases, I argue that Canada, which recently announced plans to develop its own “orphan drug framework” should not follow the United States' orphan drug model.     

The representation of street art on Flickr. Studying reception with visual content analysis

Street art is public art; it’s accessible; it’s of the people; it’s an urban voice; it’s on public view; it’s on-the-street. Nonetheless, the World Wide Web has been party responsible for street art becoming both recognised and popular. As a result, this study is investigating how street art is represented on the open photo-sharing platform, Flickr. It is a social network site offering a large portfolio of photographs showing a wide range of images, which have been categorised and classified using ‘tags’. By using a visual content analysis based on theoretically determined categories to examine the uploaded photographs, this investigation will shed light on what a selection of Flickr users recognise as street art and how they record and index it.     

Comparative Human Health Impact Assessment of Engineered Nanomaterials in the Framework of Life Cycle Assessment

For safe innovation, knowledge on potential human health impacts is essential. Ideally, these impacts are considered within a larger life‐cycle‐based context to support sustainable development of new applications and products. A methodological framework that accounts for human health impacts caused by inhalation of engineered nanomaterials (ENMs) in an indoor air environment has been previously developed. The objectives of this study are as follows: (i) evaluate the feasibility of applying the CF framework for NP exposure in the workplace based on currently available data; and (ii) supplement any resulting knowledge gaps with methods and data from the li fe c ycle a pproach and human r isk a ssessment (LICARA) project to develop a modified case‐specific version of the framework that will enable near‐term inclusion of NP human health impacts in life cycle assessment (LCA) using a case study involving nanoscale titanium dioxide (nanoTiO₂). The intent is to enhance typical LCA with elements of regulatory risk assessment, including its more detailed measure of uncertainty. The proof‐of‐principle demonstration of the framework highlighted the lack of available data for both the workplace emissions and human health effects of ENMs that is needed to calculate generalizable characterization factors using common human health impact assessment practices in LCA. The alternative approach of using intake fractions derived from workplace air concentration measurements and effect factors based on best‐available toxicity data supported the current case‐by‐case approach for assessing the human health life cycle impacts of ENMs. Ultimately, the proposed framework and calculations demonstrate the potential utility of integrating elements of risk assessment with LCA for ENMs once the data are available.